Abstract Number: 1355 • 2019 ACR/ARP Annual Meeting
A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures
Background/Purpose: Despite ACR recommendations to initiate a major therapeutic change (MTC) in rheumatoid arthritis (RA) patients with moderate/severe disease activity, our recent work has shown…Abstract Number: 2778 • 2017 ACR/ARHP Annual Meeting
Preventing Rheumatoid Arthritis: North American Perspectives of Patients and First-Degree Relatives on the Risk of Developing the Disease and of Potential Preventative Interventions
Background/Purpose: Increasingly, evidence suggests that treatment of people at risk of rheumatoid arthritis (RA) with anti-rheumatic drugs could prevent the onset of disease. Ongoing randomized…Abstract Number: 411 • 2017 ACR/ARHP Annual Meeting
Factors That Drive Treatment Recommendation during Rheumatoid Arthritis Patient´s Follow-up, Differ According to Physician Experience
Background/Purpose: The management plan for rheumatoid arthritis (RA) might be a relatively simple task if only disease activity is considered but might become more complex…Abstract Number: 1045 • 2017 ACR/ARHP Annual Meeting
The Potential Value of a Shared Decision-Making Intervention for Choices Regarding Triple Therapy in Rheumatoid Arthritis
Background/Purpose: Previous studies have shown that using Triple Therapy (a combination of 3 generic drugs) prior to a biologic, is the most cost-effective strategy for…Abstract Number: 1052 • 2017 ACR/ARHP Annual Meeting
Systematic Review of Modelling Approaches and Quality for the Cost Effectiveness of sequential Targeted Therapy in Patients with Rheumatoid Arthritis That Show an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor
Background/Purpose: Results from cost-effectiveness analysis (CEAs) comparing treatment options for patients with rheumatoid arthritis (RA) who have an inadequate response to an initial tumor necrosis…Abstract Number: 1078 • 2017 ACR/ARHP Annual Meeting
Initial Combination Therapy Versus Step-up Therapy Is More Effective and Less Costly As a Treat to Target Strategy for RA: A Markov Model Based upon the Dutch Rheumatoid Arthritis Monitoring Registry Cohorts
Background/Purpose: Adjusting medication of patients with rheumatoid arthritis (RA) until predefined disease activity targets are met, i.e. Treat to Target (T2T), is the currently recommended…Abstract Number: 1257 • 2017 ACR/ARHP Annual Meeting
A Scoping Review of Contextual Factors of Patient Decision Aids in Osteoarthritis
Background/Purpose: Patient decision aids (PDAs) have been developed to help patients make informed health care decisions that are consistent with their values and preferences. Patients…Abstract Number: 1298 • 2017 ACR/ARHP Annual Meeting
Tough Choices: Understanding the Medication Decision-Making Process for Women with Inflammatory Arthritis during Pregnancy and Lactation
Background/Purpose: With new data demonstrating medication compatibility in pregnancy and lactation, it is important to understand how this information can best reach patients. We sought…Abstract Number: 51 • 2017 Pediatric Rheumatology Symposium
The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA
Background/Purpose: We wondered if with our current physician based strategy we really do reach improvement within 3 months and inactive disease within 12 months in…Abstract Number: 779 • 2015 ACR/ARHP Annual Meeting
Mapping Perceptions of Medication Decision Making Facilitators: The Importance of Patient Context
Background/Purpose: Our objective was to derive a cognitive map of how stakeholders perceive patient-identified facilitators to establish a theoretical framework for the purpose of developing…Abstract Number: 2104 • 2015 ACR/ARHP Annual Meeting
Influence on Treatment Decision Making of Providing Numerical Ranges of Side-Effect Risks
Background/Purpose: Doctors and patients make treatment decisions after weighing benefits and harms. For harms, while people prefer treatments with smaller risks, how they react to…Abstract Number: 2269 • 2015 ACR/ARHP Annual Meeting
Rheumatologists Consider Patient Preferences and Costs When Choosing Treatments for Rheumatoid Arthritis (RA) Patients. a Cross-European Discrete Choice Experiment
Background/Purpose: Economic considerations and patient preferences are increasingly important when choosing treatments. It is not known to what extent rheumatologists across Europe account for these…Abstract Number: 2312 • 2015 ACR/ARHP Annual Meeting
Patient Preferences for Total Knee Replacement Surgery: Two Year Follow-up
Background/Purpose: Patients’ preferences for total knee replacement (TKR) may determine actual receipt of TKR and may also change over time. Yet, no study has longitudinally…Abstract Number: 2329 • 2015 ACR/ARHP Annual Meeting
Describe Treatments As ‘new’ or ‘old’ at Your Peril: Influences on Patient Decision Making
Background/Purpose: Using an example of a new drug for rheumatoid arthritis which offers comparable effectiveness and side-effect point estimates to older drugs, we explore preferences…Abstract Number: 2453 • 2015 ACR/ARHP Annual Meeting
Evidence-Based Decision Support for Pediatric Rheumatology Reduces Diagnostic Errors, with the Potential to Reduce Capacity Shortage
Background/Purpose: This projects seeks to respond to the critical shortage of pediatric rheumatologists encapsulating the diagnostic information of the field in an advanced diagnostic decision…